Q-omics provides the consensus-scored TMEM178A profile across patient tissues and cancer cell-line models. TMEM178A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM178A is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TMEM178A RNA expression shows 18,646 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, and BRCA as cancer lineages where TMEM178A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM178A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM178A survival associations across molecular data types. TMEM178A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM178A RNA expression–survival associations across cancer types. High TMEM178A expression shows unfavorable associations in KIRC, STAD, CHOL and UVM, but favorable associations in KICH and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM178A RNA expression.
This table summarizes TMEM178A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM178A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM178A shows lower tumor expression in KIRC, KIRP, KICH, LUAD, THCA and LUSC. The KIRC box plot shows higher TMEM178A RNA expression in normal versus tumor tissue (log2 FC = −3.620, t-test p < 0.001).
This table shows molecular features associated with TMEM178A in patient tissues and cancer cell lines. In patient samples, TMEM178A shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM178A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
